睿知中国疾病研究地图
候选清单0

即将招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学肿瘤医院Peking University Cancer Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07882056,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or radiologically confirmed hepatocellular carcinoma.

    入选标准第 2 条

  3. Child-Pugh class A or B (score <=7).

    入选标准第 9 条

    Poor liver function: Child-Pugh score >7, or hepatic enzymes, coagulation, bilirubin, or bone marrow function not meeting the enrollment criteria.

    排除标准第 3 条

  4. Inoperable disease, not a transplant candidate, and unsuitable for ablation or transarterial therapy, including locally advanced and oligometastatic disease. 4.1 Locally advanced: no extrahepatic metastasis; portal vein, hepatic vein, or inferior vena cava tumor thrombus permitted. 4.2 Oligometastatic: a limited number (<=5) of extrahepatic metastatic lesions (lymph node, visceral, bone, adrenal, or soft tissue; brain metastases excluded), with or without intrahepatic disease meeting the locally advanced definition. Vascular invasion is not counted in the lesion number, and lesions achieving complete response (per RECIST 1.1) after prior therapy are not counted.

    入选标准第 4 条

    No prior systemic therapy, or progression or intolerance after first-line systemic therapy, with more than 3 weeks since the last dose.

    入选标准第 7 条

    Prior selective internal radiation therapy or yttrium-90 hepatic arterial therapy.

    排除标准第 8 条

  5. ECOG performance status 0-1 within 1 week before enrollment.

    入选标准第 8 条

    ECOG performance status >=2.

    排除标准第 2 条

  6. Hematology: hemoglobin >=90 g/L; white blood cell count >=3.0 x 10\^9/L; absolute neutrophil count >=1.5 x 10\^9/L; platelet count >=75 x 10\^9/L.

    入选标准第 10 条

    ALT and AST <=5 x upper limit of normal (ULN); alkaline phosphatase <=5 x ULN; total bilirubin <=3 x ULN; albumin >=28 g/L.

    入选标准第 12 条

    Serum creatinine <=1.5 x ULN, or creatinine clearance >=50 mL/min calculated by the Cockcroft-Gault formula.

    入选标准第 13 条

  7. At least one measurable lesion per RECIST 1.1.

    入选标准第 5 条

  8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07882056,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age >= 18 years, male or female.
  2. Histologically or radiologically confirmed hepatocellular carcinoma.
  3. Barcelona Clinic Liver Cancer (BCLC) stage B or C.
  4. Inoperable disease, not a transplant candidate, and unsuitable for ablation or transarterial therapy, including locally advanced and oligometastatic disease. 4.1 Locally advanced: no extrahepatic metastasis; portal vein, hepatic vein, or inferior vena cava tumor thrombus permitted. 4.2 Oligometastatic: a limited number (<=5) of extrahepatic metastatic lesions (lymph node, visceral, bone, adrenal, or soft tissue; brain metastases excluded), with or without intrahepatic disease meeting the locally advanced definition. Vascular invasion is not counted in the lesion number, and lesions achieving complete response (per RECIST 1.1) after prior therapy are not counted.
  5. At least one measurable lesion per RECIST 1.1.
  6. All lesions can safely receive stereotactic body radiotherapy.
  7. No prior systemic therapy, or progression or intolerance after first-line systemic therapy, with more than 3 weeks since the last dose.
  8. ECOG performance status 0-1 within 1 week before enrollment.
  9. Child-Pugh class A or B (score <=7).
  10. Hematology: hemoglobin >=90 g/L; white blood cell count >=3.0 x 10\^9/L; absolute neutrophil count >=1.5 x 10\^9/L; platelet count >=75 x 10\^9/L.
  11. INR <=2.3, or prothrombin time exceeding the upper limit of normal by <=6 seconds.
  12. ALT and AST <=5 x upper limit of normal (ULN); alkaline phosphatase <=5 x ULN; total bilirubin <=3 x ULN; albumin >=28 g/L.
  13. Serum creatinine <=1.5 x ULN, or creatinine clearance >=50 mL/min calculated by the Cockcroft-Gault formula.
  14. Urine protein <2+ (patients with urine protein >=2+ may undergo 24-hour urine protein quantification and are eligible if the 24-hour urine protein is <1.0 g).
  15. Patients with active hepatitis B virus (HBV) infection: HBV-DNA <500 IU/mL (or <2500 copies/mL if only copy/mL is available) and willingness to receive antiviral therapy throughout the study; patients positive for hepatitis C virus (HCV) RNA must receive standard antiviral therapy, with hepatic enzyme elevation <=CTCAE grade 1.
  16. Women of childbearing potential (generally 15-49 years) must have a negative serum or urine pregnancy test within 14 days before enrollment and be willing to use adequate contraception during the study and for 8 weeks after the last dose of study drug; men must be surgically sterile or agree to adequate contraception during the study and for 8 weeks after the last dose.
  17. Voluntary participation with signed informed consent, good compliance, and willingness to undergo follow-up.

排除标准:Exclusion Criteria:

  1. Age <18 years.
  2. ECOG performance status >=2.
  3. Poor liver function: Child-Pugh score >7, or hepatic enzymes, coagulation, bilirubin, or bone marrow function not meeting the enrollment criteria.
  4. Hepatic encephalopathy, massive ascites, or abdominal infection within 1 month.
  5. Brain metastases.
  6. Malignant pleural effusion.
  7. Prior radiotherapy to any site requiring treatment in this study (risk of field overlap causing excessive irradiation of normal tissue).
  8. Prior selective internal radiation therapy or yttrium-90 hepatic arterial therapy.
  9. Tumor directly invading the stomach, duodenum, small intestine, or large intestine; or tumor within 3 mm of the spinal cord.
  10. Maximum diameter of any single lesion >15 cm.
  11. Sum of the maximum diameters of all intrahepatic lesions, or the maximum diameter of a single confluent lesion, >20 cm.
  12. More than 5 discrete intrahepatic HCC lesions.
  13. Normal liver volume <700 mL.
  14. Known history of allogeneic organ or hematopoietic stem cell transplantation, or planned transplantation.
  15. Known allergy to iparomlimab and tuvonralimab, bevacizumab, or drug excipients, or severe hypersensitivity to any other monoclonal antibody.
  16. Live attenuated vaccination within 4 weeks before the first dose or planned during the study.
  17. Severe active autoimmune disease.
  18. Any other malignancy, except adequately treated basal cell or squamous cell skin carcinoma or cervical carcinoma in situ.
  19. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
  20. Within 6 months before enrollment: myocardial infarction, severe or unstable angina, NYHA class >=2 heart failure, poorly controlled arrhythmia, or symptomatic congestive heart failure.
  21. Coagulation abnormality with bleeding tendency, or currently receiving thrombolytic, anticoagulant, or antiplatelet therapy.
  22. Known hereditary or acquired bleeding or thrombotic tendency, such as hemophilia, coagulation disorders, or severe thrombocytopenia.
  23. Risk of gastrointestinal bleeding, including: (1) active peptic ulcer; (2) melena or hematemesis within 1 month; (3) gastroscopy showing ulcer or bleeding lesions, esophagogastric varices with red color signs (+), or variceal diameter >1 cm. Also: history of psychotropic drug abuse or drug addiction, or other severe medical or psychiatric illness, or laboratory abnormality that may increase study risk, confound results, or render the patient unsuitable in the investigator's judgment.

引自 ClinicalTrials.gov, NCT07882056, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07882056,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07882056